Progress of chimeric antigen receptor T-cell for treatment of follicular lymphoma
10.3760/cma.j.issn.1006-9801.2019.10.018
- VernacularTitle: 嵌合抗原受体T细胞治疗滤泡淋巴瘤的研究进展
- Author:
Hailing NING
1
;
Xiulian ZHANG
Author Information
1. Department of Hematology, the First Hospital of Shanxi Medical University, Taiyuan 030001, China
- Publication Type:Review
- Keywords:
Lymphoma, follicular;
Chimeric antigen receptor T-cell;
CD19;
Anti-CD20 monoclonal antibody
- From:
Cancer Research and Clinic
2019;31(10):717-720
- CountryChina
- Language:Chinese
-
Abstract:
Follicular lymphoma (FL) is usually occult, with a wide range of disease manifestations and prognosis. In recent years, with the combination of anti-CD20 monoclonal antibody and standard chemotherapy methods, as well as the use of immunomodulators and hematopoietic stem cell transplantation, the survival rate of FL patients has been greatly improved, but it is still considered to be an incurable disease. Recent studies have shown that the chimeric antigen receptor T-cell (CAR-T) therapy can improve the survival rate and the prognosis of FL patients. The article will elaborate on the mechanism, clinical research progress, adverse reactions and limitations of CAR-T in the treatment of FL.
